HSPG2 and neoplasm: shCXCL3 treatment inhibited the tumor-sphere formation ability of CD133+ PLC/PRF/5 cells, and the tumor-sphere formation ability of CD133− PLC/PRF/5 cells was also impaired after CXCL3 knockdown, though it was not so obvious compared with CD133+ cell group.